A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)

Dietger Niederwieser, Paul Richardson, Michel Attal, Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios Dimopoulosu, Jeffrey Shang-Yi Huan, Jiri Minarik, Michele Cavo, Sandrine Mace, H Miles Prince, Kathryn P Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin Show all